Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
- Registration Number
- NCT00530881
- Lead Sponsor
- Phenomix
- Brief Summary
This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2 diabetes ) or placebo. The drug is a "DPP4 inhibitor"
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- Type 2 diabetes mellitus treatment with metformin +/- TZD
Exclusion Criteria
- Type 1 diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 4 PHX1149 - 3 active, 1 placebo PHX1149 -
- Primary Outcome Measures
Name Time Method postprandial blood glucose
- Secondary Outcome Measures
Name Time Method fasting blood glucose, HbA1c, safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of PHX1149 as a DPP4 inhibitor in Type 2 Diabetes Mellitus?
How does PHX1149 compare to other DPP4 inhibitors like sitagliptin in managing Type 2 Diabetes?
Which biomarkers are associated with response to DPP4 inhibitors in Type 2 Diabetes patients?
What are the potential adverse events of PHX1149 and how do they compare to standard-of-care DPP4 inhibitors?
Are there combination therapies involving PHX1149 and GLP-1 agonists for enhanced glycemic control in Type 2 Diabetes?
Trial Locations
- Locations (1)
Multiple Sites
🇺🇸san Diego, California, United States